Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 5/20 | 0.60 |
| ▸ | KCNQ4 | P56696 | 4/20 | 0.51 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.51 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20129839 | 0.84 | KCNQ2 (0.53) | KCNQ2KCNQ4KCNQ3KCNQ5CYP1A2 | |
| SCHEMBL14638232 | 0.82 | PKM (0.50) | KCNQ2KCNQ4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10669484 | 0.81 | KCNQ2 (0.50) | KCNQ2KCNQ4KCNQ3KCNQ5CYP1A2 | |
| SCHEMBL15172819 | 0.79 | KCNQ2 (0.71) | KCNQ2KCNQ4KCNQ3KCNQ5CYP1A2 | |
| SCHEMBL19700186 | 0.78 | KCNQ2 (0.79) | KCNQ2KCNQ4KCNQ3KCNQ5CYP1A2 | |
| SCHEMBL19700187 | 0.78 | KCNQ2 (0.59) | KCNQ2KCNQ4KCNQ3KCNQ5CYP1A2 | |
| SCHEMBL19700144 | 0.77 | KCNQ2 (0.63) | KCNQ2KCNQ4KCNQ3KCNQ5CYP1A2 | |
| SCHEMBL26974038 | 0.77 | KCNQ2 (0.58) | KCNQ2KCNQ4KCNQ3KCNQ5HDAC1 | |
| SCHEMBL15996908 | 0.76 | KCNQ2 (0.68) | KCNQ2KCNQ4KCNQ3KCNQ5CYP1A2 | |
| SCHEMBL15996880 | 0.76 | KCNQ2 (0.74) | KCNQ2KCNQ4KCNQ3KCNQ5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100323015-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | BAUSCH HEALTH COMPANIES INC. (CA) | 2010-12-23 | — | — | US | claimed |
| US-20100323016-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | SOLTA MEDICAL DUTCH HOLDINGS B.V. (NL) | 2010-12-23 | — | — | US | claimed |
| US-20100120906-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2010-05-13 | — | — | US | claimed |
| WO-2010009433-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2010-01-21 | — | — | WO | claimed |
| CN-102170879-B | Modified release formulation and methods of use | VALEANT PHARMACEUTICALS INT | 2014-03-05 | — | — | CN | disclosed |
| EP-2525660-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | Valeant Pharmaceuticals International (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2525788-A2 | NOVEL RETIGABINE COMPOSITION | Glaxo Group Limited (GB) | 2012-11-28 | — | — | EP | disclosed |
| CN-102802615-A | Novel retigabine compositions | GLAXO GROUP LTD | 2012-11-28 | — | — | CN | disclosed |
| US-20120288544-A1 | NOVEL RETIGABINE COMPOSITION | GLAXO GROUP LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| WO-2011089126-A3 | NOVEL RETIGABINE COMPOSITION | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
| CN-102170879-A | Modified release formulation and methods of use | VALEANT PHARMACEUTICALS INT | 2011-08-31 | — | — | CN | disclosed |
| WO-2011090923-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100323015-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | BAUSCH HEALTH COMPANIES INC. (CA) | 2010-12-23 | — | — | US | disclosed |
| US-20100323015-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | BAUSCH HEALTH COMPANIES INC. (CA) | 2010-12-23 | — | — | US | disclosed |
| US-20100120906-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120906-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010009433-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010009433-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-0956281-A1 | NOVEL MODIFICATIONS TO 2-AMINO-4-(4-FLUOROBENZYLAMINO)-1-ETHOXYCARBONYL-AMINOBENZENE AND PROCESSES FOR PREPARING SAID COMPOUND | ASTA Medica Aktiengesellschaft (DE) | 1999-11-17 | — | — | EP | disclosed |
| WO-1998031663-A1 | NOVEL MODIFICATIONS TO 2-AMINO-4-(4-FLUOROBENZYLAMINO)-1-ETHOXYCARBONYL-AMINOBENZENE AND PROCESSES FOR PREPARING SAID COMPOUND | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1998-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323015-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | HNMT, HCN3, CACNA1E | KCNQ2 174/4885KCNQ4 264/4885KCNQ3 308/4885 |
| US-20100120906-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | HNMT, HCN3, HRH4 | KCNQ2 301/4885KCNQ4 383/4885KCNQ3 433/4885 |
| US-20120288544-A1 | NOVEL RETIGABINE COMPOSITION | CNR2, CNR1, CACNA1B | KCNQ2 25/4885KCNQ4 61/4885KCNQ3 64/4885 |
| US-20100323016-A1 | MODIFIED RELEASE FORMULATION AND METHODS OF USE | HNMT, HCN3, CACNA1E | KCNQ2 174/4885KCNQ4 264/4885KCNQ3 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.